Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (2053)	1/26/1998 10:39:00 PM
From: Dauntless	Read Replies (4) \| Respond to of 7041

Sorry but I disagree with your interpretation - I feel that the reason for not giving the levels is that they were indeterminable. The title of the study - "Gas chromatographic determination of phentolamine (Regitine)in human plasma and urine" speaks very plainly. They certainly would have provided the numbers if they were measureable - why else would they pull samples? Perhaps you should take the time to re-read the paper - I'll fax it to you if you'd like. And furthermore, you've missed a point equally important - the Jan. 15th Asensio press release was based entirely on worthless science. The analytic technique employed was completely UNVALIDATED. There was no attempt to provide even the most basic details of their technique. This was an early study in an effort by Ciba-Geigy to develop an accurate assay for low levels of phentolamine in plasma. They finally achieved success in 1981 & proved - as is now taught in modern medical texts - that phentolamine, delivered in a standard dissolving oral tablet - does not result in significant blood levels because of rapid metabolic clearing. The Asensio press release reveals shoddy research & an all too clear ulterior motive. Good luck with your Vivus stock - it appears to be rebounding nicely.